COMMUNIQUÉS West-GlobeNewswire

Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2
18/03/2024
British Medical Journal Open publishes paper detailing the results of the international Phase II human trial for LSALT peptide targeting acute lung and kidney inflammation in hospitalized patients infected with SARS-CoV [...]
Major shareholder announcement – AIM International Mutual Funds
18/03/2024
ANNOUNCEMENT NO. 257 Major shareholder announcement Major shareholder announcement – AIM International Mutual Funds Pursuant to Section 30 of the Danish Capital Markets Act, it is hereby announced that Invesco Ltd. has [...]
Major shareholder announcement – Invesco Ltd.
18/03/2024
ANNOUNCEMENT NO. 256 Major shareholder announcement Major shareholder announcement – Invesco Ltd. Pursuant to Section 30 of the Danish Capital Markets Act, it is hereby announced that Invesco Ltd. has informed [...]
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer
18/03/2024
Industry Veteran with Extensive Experience in Retinal Disease Research and Strong Track Record in Advancing Programs Through Clinical Development ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical [...]
Sequel’s twiist™ Automated Insulin Delivery System Receives FDA 510(k) Clearance
18/03/2024
Device Bundles Latest Technology to Deliver Significant Advancements for Insulin Management for People with Type 1 Diabetes MANCHESTER, N.H., March 18, 2024 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing [...]
First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference
18/03/2024
Poster presentations to highlight new quantitative and serologic diagnostic methods for Celiac Disease detection and determination of intestinal mucosal health New tools may serve as companion diagnostics for [...]
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
18/03/2024
―Industry veteran with late-stage clinical development, medical affairs, and regulatory experience; well-positioned to advance losmapimod towards a potential regulatory submission and approval ― ― Interim Chief Medical [...]
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
18/03/2024
WATERTOWN, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious [...]
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
18/03/2024
The company announced the initiation of RAPIDe-3, the Phase 3 clinical trial evaluating the efficacy and safety of deucrictibant immediate-release capsule (PHVS416) for the treatment of HAE attacks ZUG, Switzerland, [...]
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 29 février 2024
18/03/2024
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 29 février 2024 En application de l'article L. 233-8 II du code de commerce et de l'article 222-12-5 du règlement général de l'AMF, [...]
Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer
18/03/2024
MALVERN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and [...]
BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing
18/03/2024
Acquisition creates leading phage therapy company with an advanced pipeline that includes two Phase 2 assets, BX004 for the treatment of chronic pulmonary infections in cystic fibrosis (“CF”) patients and BX211 for the [...]
Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress
18/03/2024
A successful year including NASDAQ listing and positive results from two Phase 3 programs in OCS-01: Phase 3 Stage 1 DIAMOND trial for Diabetic Macular Edema (DME), and Phase 3 OPTIMIZE-1 trial for inflammation and pain [...]
CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies
18/03/2024
SINGAPORE, March 18, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to [...]
Completion of share buy-back program
18/03/2024
Company Announcement COPENHAGEN, Denmark; March 18, 2024 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on March 15, 2024 On February 14, 2024, Genmab announced the initiation [...]
OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform
18/03/2024
Poster Presentations to highlight the latest research on OBI-992 (anti-TROP2 ADC) and OBI’s novel GlycOBI ADC platform TAIPEI, Taiwan, March 18, 2024 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (TPEx: 4174) today announced [...]
SENISCA secures additional £3.7 million financing to support rapid development of senotherapeutic platform to treat age-related disease
18/03/2024
SENISCA secures additional £3.7 million financing to support rapid development of senotherapeutic platform to treat age-related disease £3.7 million seed financing supported by consortium of new and existing investors [...]
ONWARD® Medical Successfully Completes Benchmark Testing on Path to Commercialize ARC-EX® System
18/03/2024
Third-party tests from leading US lab confirm printed circuit board assembly (PCBA) conforms to prevailing international electrical standards, a requirement for commercial launch THIS PRESS RELEASE CONTAINS INSIDE [...]
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed
18/03/2024
Reimbursements deferred by 18 months to start in January 2026 instead of July 2024 Saint-Herblain (France), March 18, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced [...]

Pages